AEON Biopharma, Inc. (AEON)

AEON Biopharma, Inc. (AEON) is a Biotechnology company in the Healthcare sector listed on the AMEX.

As of Oct 23, 2026: market cap $11.6M; returns 1 day +2.7%, 1 week +3.4%, 1 year -73.6%.

AEON Biopharma, Inc. (AEON) is a clinical-stage biopharmaceutical company focused on developing and commercializing botulinum toxin-based therapies for debilitating medical conditions. Their lead product, ABP-450 (prabotulinumtoxinA) injection, is a proposed biosimilar to BOTOX, targeting the $3.5 billion therapeutic neurotoxin market.

Groups AEON belongs to

• Clinical Stage Biopharma
• Biotechnology
• Biopharmaceutical
• Healthcare
• Biologics
• Neuroscience
• Neurological Disorders
• Clinical Stage
• Pharmaceuticals
• CNS Disorders

AEON financial model: income statement, cash flow and balance sheet